Literature DB >> 15037283

Human umbilical cord cells for cardiovascular tissue engineering: a comparative study.

Alexander Kadner1, Gregor Zund, Christine Maurus, Christian Breymann, Sidika Yakarisik, Gregor Kadner, Marko Turina, Simon P Hoerstrup.   

Abstract

OBJECTIVE: Tissue engineering of viable, autologous cardiovascular replacements with the potential to grow, repair and remodel represents an attractive approach to overcome the shortcomings of available replacements for the repair of congenital cardiac defects. Currently, vascular myofibroblast cells represent an established cell source for cardiovascular tissue engineering. Cell isolation requires the invasive harvesting of venous or arterial vessel segments prior to scaffold seeding, a technique which may not be preferable, especially in pediatric patients. This study evaluates cells isolated from human umbilical cord artery, umbilical cord vein and whole cord as alternative autologous cell sources for cardiovascular tissue engineering.
METHODS: Cells were isolated from human umbilical cord artery (UCA), umbilical cord vein (UCV), whole umbilical cord (UCC) and saphenous vein segments (VC), and were expanded in culture. All three expanded cell groups were seeded on bioabsorbable copolymer strips and grown in vitro for 28 days. Isolated cells were characterized by flow cytometry, histology, immunohistochemistry, proliferation assays and compared to VC. Morphological analysis of the seeded polymer strips included histology, immunohistochemistry, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transmission electron microscopy (TEM), scanning electron microscopy (SEM) and uniaxial stress testing.
RESULTS: UCA, UCV and UCC demonstrated excellent cell growth properties comparable to VC. Following isolation, all three cell groups showed myofibroblast-like morphology and characteristics by staining positive for alpha-smooth muscle actin (ASMA) and vimentin. Histology and immunohistochemistry of seeded polymers showed good tissue and extracellular matrix formation containing collagen I, III and elastin. TEM showed viable myofibroblasts and the deposition of collagen fibrils and progressive growing tissue formation, with a confluent surface, was observed in SEM. No difference was found among the mechanical properties of UCA, UCV, UCC and VC tissue engineered constructs.
CONCLUSIONS: Tissue engineering of cardiovascular constructs by using UCA, UCV and UCC is feasible in an in vitro environment. Cell growth, morphology, characteristics and tissue formation were comparable between UCA, UCV, UCC and VC. UCC represent an attractive, readily available autologous cell source for cardiovascular tissue engineering offering the additional benefits of utilizing juvenile cells and avoiding the invasive harvesting of intact vascular structures.

Entities:  

Mesh:

Year:  2004        PMID: 15037283     DOI: 10.1016/j.ejcts.2003.12.038

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  18 in total

Review 1.  Musculoskeletal tissue engineering with human umbilical cord mesenchymal stromal cells.

Authors:  Limin Wang; Lindsey Ott; Kiran Seshareddy; Mark L Weiss; Michael S Detamore
Journal:  Regen Med       Date:  2011-01       Impact factor: 3.806

Review 2.  Umbilical cord cells as a source of cardiovascular tissue engineering.

Authors:  Christian Breymann; Dörthe Schmidt; S P Hoerstrup
Journal:  Stem Cell Rev       Date:  2006       Impact factor: 5.739

Review 3.  Stem cells in the umbilical cord.

Authors:  Mark L Weiss; Deryl L Troyer
Journal:  Stem Cell Rev       Date:  2006       Impact factor: 5.739

Review 4.  Stem cell sources for vascular tissue engineering and regeneration.

Authors:  Vivek K Bajpai; Stelios T Andreadis
Journal:  Tissue Eng Part B Rev       Date:  2012-07-03       Impact factor: 6.389

5.  Size-sieved subpopulations of mesenchymal stem cells from intervascular and perivascular equine umbilical cord matrix.

Authors:  B Corradetti; A Lange-Consiglio; M Barucca; F Cremonesi; D Bizzaro
Journal:  Cell Prolif       Date:  2011-06-06       Impact factor: 6.831

Review 6.  Tissue engineering on matrix: future of autologous tissue replacement.

Authors:  Benedikt Weber; Maximilian Y Emmert; Roman Schoenauer; Chad Brokopp; Laura Baumgartner; Simon P Hoerstrup
Journal:  Semin Immunopathol       Date:  2011-01-29       Impact factor: 9.623

Review 7.  Vibrational spectroscopy and imaging: applications for tissue engineering.

Authors:  William Querido; Jessica M Falcon; Shital Kandel; Nancy Pleshko
Journal:  Analyst       Date:  2017-10-23       Impact factor: 4.616

Review 8.  Therapeutic potentials of mesenchymal stem cells derived from human umbilical cord.

Authors:  Cun-Gang Fan; Qing-jun Zhang; Jing-ru Zhou
Journal:  Stem Cell Rev Rep       Date:  2011-03       Impact factor: 5.739

9.  Human Umbilical Cord Mesenchymal Stromal Cell Transplantation in Myocardial Ischemia (HUC-HEART Trial). A Study Protocol of a Phase 1/2, Controlled and Randomized Trial in Combination with Coronary Artery Bypass Grafting.

Authors:  Alp Can; Ahmet Tulga Ulus; Ozgur Cinar; Ferda Topal Celikkan; Erdal Simsek; Mesut Akyol; Ugur Canpolat; Murat Erturk; Fadil Kara; Osman Ilhan
Journal:  Stem Cell Rev Rep       Date:  2015-10       Impact factor: 5.739

10.  Effect of initial seeding density on human umbilical cord mesenchymal stromal cells for fibrocartilage tissue engineering.

Authors:  Limin Wang; Kiran Seshareddy; Mark L Weiss; Michael S Detamore
Journal:  Tissue Eng Part A       Date:  2009-05       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.